OBJECTIVES: OncoLitBank is a registry of published oncology trials and Health Technology Assessments aimed to help provide a platform for secondary data analytics in the field of oncology. To demonstrate the utility and functionality of OncoLitBank, we conducted a basic indirect treatment comparison (ITC) between gemcitabine/nab-paclitaxel (GemNpac) and gemcitabine/capecitabine(GemCap) combinations which were each tested against gemcitabine but not against each other for treatment of metastatic pancreatic cancer. METHODS: Using OncoLitBank, data for metastatic pancreatic cancer were filtered for treatment-comparator arms of interest by using built-in interactive features. Two phase III randomized controlled trials (RCTs) comparing GemCap vs Gem, while 1 RCT comparing GemNpac vs Gem were included for the ITC. Data on overall response rate (ORR), 1-year survival, overall survival (OS), progression-free survival (PFS), and grade 3-4 adverse events (AEs) were pooled for the 2 RCTs comparing GemCap vs Gem using RevMan 5.0. Pooled risk ratios (RRs) and mean differences (MD) for the 2 studies were derived for dichotomous and continuous outcome variables respectively and compared to the single RCT that evaluated GemNpac vs Gem to derive the ITC RRs and MDs using the Canadian Agency for Drugs and Technologies in Health (CADTH) ITC application which employs Bucher et al. (1997) method. RESULTS: The use of OncoLitBank was successful and eliminated the need to conduct a new systematic review to perform the ITC leading to a quick turn-around of tasks at hand. Results demonstrated that GemNpac was not superior to GemCap in ORR, 1-year survival, OS, PFS and grade 3-4 AEs, as no significant differences was detected. CONCLUSIONS: OncoLitBank provides users with a robust data platform that can be easily used for systematic reviews, conduct meta-analyses through direct orindirect comparisons, inform economic models, landscape analyses, value dossiers, create target product profiles and value development plans.